Biogen

BYOOVIZ

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / BYOOVIZ – Q5124

Manufacturer:

Biogen

Name:

BYOOVIZ

HCPCS Code Descriptor:

Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg

Category:

Q Code

HCPCS:

Q5124

NDC(s):

64406-0019-01

Primary Type:

Opthalmic Biosimilar

Generic/Specialty Status:

LUCENTIS Biosimilar

Route of Administration:

Intraocular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About:

BYOOVIZ is an Opthalmic Biosimilar drug manufactured by Biogen and administered via the Intraocular route of administration. The Q Code: Q5124 is aligned to the drug BYOOVIZ.

Byooviz is an injection into the eye that is used to treat certain eye disorders and diseases. This medication prevents the formation of new blood vessels under the retina. Byooviz is manufactured by Biogen and is a biosimilar to the medication Lucentis (J2778). This medication is currently aligned to the HCPCS code Q5124 and has been since April 2022. Patient assistance programs for this medication can be found through Biogen Biosimilar Support Services.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

4/1/22

HCPCS Effective Date:

1/1/23

HCPCS Short Description:

Inj. byooviz, 0.1 mg

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.byoovizhcp.com/support/index.html

BYOOVIZ - Q5124